Search results
AHN Honors Neurosciences
Erie News Now Plus· 12 hours agoThe event featured music, dinner and charity auctions, with the money raised benefiting neurosciences at the hospital.
Alto Neuroscience schizophrenia treatment shows good phase 1 results
Seeking Alpha· 4 days agoALTO-101, a PDE4 inhibitor by Alto Neuroscience, shows promising results in phase 1 trial for...
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In...
Benzinga via Yahoo Finance· 4 days agoRecently listed Alto Neuroscience Inc (NYSE:ANRO) released results from its healthy volunteer Phase...
New Haven and neuroscience: Match made in heaven?
Hartford Business Journal· 2 days agoThe announcement last spring by Yale New Haven Health of plans to develop an $838 million neurosciences facility on its St. Raphael campus marked New...
Alto Neuroscience reports positive Phase 1 results for ALTO-101 By Investing.com
Investing.com· 4 days agoAlto Neuroscience, Inc. (NYSE: ANRO) announced today that its Phase 1 study of ALTO-101, a novel...
▶️ Listen Now: The benefits of teaching kids about neuroscience
WBEZ 91.5 Chicago· 4 days agoWhen people are science literate, they could be more health literate too.
Naps Crucial For Brain Development and Memory in Kids - Neuroscience News
Neuroscience News· 2 days agoSummary: A new study aims to examine the role of napping in brain development among infants and...
AI Links Gut Microbiome to Alzheimer's - Neuroscience News
Neuroscience News· 5 days agoSummary: Researchers are pioneering the use of artificial intelligence to explore how the gut...
...Renowned Neurosurgeon Dr. Adam Kanter as Executive Medical Director of its Nationally Ranked...
CW39 NewsFix· 5 days agoHoag announced today Adam Kanter, M.D., F.A.A.N.S, has been named Executive Medical Director of the Pickup Family Neurosciences Institute. Dr. Kanter will lead a multidisciplinary ...
To be better at neuroscience, Biogen will invest outside the therapeutic area
FierceBiotech· 3 days agoTo be a better neuroscience company, Biogen is going to have to diversify—outside of the therapeutic...